Clinical Trial Update: Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial evaluated AFQ056 (mavoglurant) for safety and efficacy in adolescents with Fragile X syndrome; results were posted in 2015 after study completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fragile Syndrome

Drugs mentioned

• AFQ056 (mavoglurant)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Fragile X Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2015-05-12